EUCTR2020-002242-17-GB进行中（未招募）1 期
A randomised, double-blind, placebo-controlled, phase 2 evaluation of the efficacy and mechanism of trientine in patients with hypertrophic cardiomyopathy. - TEMPEST
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 172
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent.
- •2. Age 18-70 inclusive.
- •3. Hypertrophic cardiomyopathy (HCM), as defined by the European Society of Cardiology HCM guidelines as: a wall thickness =15 mm in one or more LV myocardial segments that is not explained solely by loading conditions”. The same definition is applied to first-degree relatives of patients with HCM i.e. all participants are required to have a LV wall thickness =15 mm. Wall thickness is as measured on the most recent cardiovascular magnetic resonance (CMR) scan performed prior to the baseline visit. If CMR has not been performed previously, wall thickness measurement should be taken from the most recent echocardiogram performed prior to the baseline visit .
- •(It is recognised that in the European Society of Cardiology guidelines a clinical diagnosis of HCM in first-degree relatives requires a wall thickness that is less than this value, however =15 mm is applied here in order to ensure that all participants have an unequivocal phenotype).
- •4. New York Heart Association class I, II or III at the most recent clinical assessment performed prior to the baseline visit.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 157
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •1. Previous or planned septal reduction therapy.
- •2. Previously documented myocardial infarction or severe coronary artery disease.
- •3.Uncontrolled hypertension, defined as a systolic blood pressure of >180mmHg or a diastolic blood pressure of > 100mmHg at Visit 1.
- •4.Known LV EF < 50%, as measured on the most recent CMR scan performed prior to the baseline visit. If CMR has not been performed previously, the most recent echocardiogram performed prior to the baseline visit should be used.
- •5. Previously documented persistent atrial fibrillation.
- •6. Anaemia, defined as haemoglobin being below the local site normal reference range, at Visit 1.
- •7. Iron deficiency, defined as serum iron being below the local site normal reference range, at Visit 1.
- •8. Copper deficiency, defined as serum copper being below the normal reference range, at Visit 1.
- •9. Pacemaker or implantable cardioverter defibrillator.
- •10. Known severe valvular heart disease, as demonstrated on the most recent heart imaging performed prior to the baseline visit.
- •11. Previously documented other cardiomyopathic cause of myocardial hypertrophy (e.g. amyloidosis, Fabry disease, mitochondrial disease).
- •12. History of hypersensitivity to any of the components of the investigational medicinal product (IMP).
- •13. Known contraindication to MRI scanning.
- •14. Pregnancy, lactation or planning pregnancy. Women of childbearing capacity are required to have a negative serum pregnancy test before treatment , must agree to pregnancy tests at study visits as defined in the Section 8 and must agree to maintain highly effective contraception as defined in Section 8 during the study.
- •15. Any medical condition, which in the opinion of the Investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study.
研究者
相似试验
进行中（未招募）
1 期
A phase 3 trial to evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids in adults with moderate to severe atopic dermatitis. ECZTRA 3 (ECZema TRAlokinumab trial no. 3)MedDRA version: 20.0 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858Atopic DermatitisEUCTR2017-002065-21-GBEO Pharma A/S492
已完成
2 期
A randomised trial of Enbrel (Etanercept) administered epidurally for the treatment of lumbosacral pain (sciatica)Sciatic painAnaesthesiology - Pain managementACTRN12609000207213Bioassets Development Corporation40
进行中（未招募）
1 期
A phase 3 trial to evaluate the efficacy and safety of tralokinumab in adults with moderate to severe atopic dermatitisAtopic DermatitisEUCTR2016-004200-65-ESEO Pharma A/S780
已完成
3 期
A randomised, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids in subjects with moderate-to-severe atopic dermatitis who are candidates for systemic therapyatopic dermatitisNL-OMON46483TFS Trial Form Support BV43
进行中（未招募）
1 期
A phase 3 trial to evaluate the efficacy and safety of tralokinumab in adults with moderate to severe atopic dermatitis (ECZTRA 2)Atopic DermatitisEUCTR2016-004201-13-PLEO Pharma A/S780